Locally Advanced Pancreatic Cancer Market Growth Outlook Reveals A CAGR Of 10.2% And A Market Value Of $1.71 Billion By 2030
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Locally Advanced Pancreatic Cancer Market Growth Analysis: How Will Revenue Expand During The Forecast Period?
The market for locally advanced pancreatic cancer experienced a significant upswing recently, projecting an expansion from $1.05 billion in 2025 to $1.16 billion by 2026, driven by a compound annual growth rate of 10.5%. This historical expansion was fueled by factors such as late detection of pancreatic cancer, a restricted number of patients eligible for surgery when the disease is locally advanced, the long-standing prevalence of gemcitabine chemotherapy, unsatisfactory overall survival statistics, and an increase in hospital-based cancer treatment services.
The market for locally advanced pancreatic cancer is poised for significant expansion in the coming years, projected to reach an impressive $1.71 billion by 2030, fueled by a compound annual growth rate of 10.2%. This anticipated surge is underpinned by several key drivers, including the broader implementation of combination therapy strategies, a rise in the utilization of Stereotactic Body Radiation Therapy (SBRT), increased financial backing for pancreatic cancer investigations, a heightened emphasis on tailored cancer treatments, and the expanding accessibility of state-of-the-art medical facilities. During this forecast period, prominent market developments are expected to involve a greater incorporation of combined chemotherapy treatments, a growing trend towards the use of neoadjuvant therapies, a more concentrated effort on reducing tumor size to improve surgical candidacy, an amplified role for radiation therapy in managing localized disease, and a stronger commitment to integrated treatment strategy development involving various medical specialties.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21214&type=smp
Locally Advanced Pancreatic Cancer Market Demand Drivers Creating New Revenue Opportunities
Heightened tobacco usage is anticipated to be a primary catalyst for the expansion of markets focused on locally advanced pancreatic cancer. Tobacco, derived from a plant whose leaves are processed into items like cigarettes and cigars, contains nicotine, a substance recognized for its addictive properties and strong association with severe health conditions, including cancer and cardiac ailments. Several elements contribute to the escalating prevalence of tobacco consumption, such as readily available access, economic feasibility, aggressive marketing strategies employed by tobacco companies, the societal acceptance observed in certain regions, and smoking as a coping mechanism for stress. Given that tobacco consumption significantly elevates the risk of developing locally advanced pancreatic cancer by contributing to a higher occurrence of pancreatic tumors, its role in market growth is pronounced. As an illustration, a study released in October 2024 by the European Respiratory Society (ERS), a non-profit entity based in Switzerland, highlighted a substantial upswing in smoking tendencies among younger demographics, demonstrating an increase from 22.5% of participants who were smokers in 2022 to 40.1% in 2024. Consequently, the escalating consumption of tobacco is directly fueling the progression of the locally advanced pancreatic cancer market.
Locally Advanced Pancreatic Cancer Market Segment Analysis And Revenue Opportunities
The locally advanced pancreatic cancer market covered in this report is segmented –
1) By Therapy: Chemotherapy, Radiation Therapy
2) By Route Of Administration: Oral, Injectables, Other Routes Of Administrations
3) By End-User: Hospital, Specialty Clinics, Research Institutions, Other End-Users
Subsegments:
1) By Chemotherapy: Gemcitabine-based Chemotherapy, FOLFIRINOX Chemotherapy
2) By Radiation Therapy: External Beam Radiation Therapy, Stereotactic Body Radiation Therapy (SBRT)
Locally Advanced Pancreatic Cancer Market Trends Driving Strategic Industry Expansion
In the market for locally advanced pancreatic cancer, key players are concentrating on creating novel therapeutic agents, including orphan drugs. These efforts aim to expand treatment availability, improve patient results, and tackle the significant unmet medical requirements presented by this challenging illness. Orphan drugs, intended for rare conditions affecting limited populations, receive encouragement through governmental incentives like tax breaks and periods of market exclusivity to foster their creation. As an illustration, in January 2025, Actuate Therapeutics Inc., a pharmaceutical entity based in the United States, revealed that their investigational compound, Elraglusib, identified as a GSK-3ß inhibitor, had been granted Orphan Drug Designation by both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the management of pancreatic ductal adenocarcinoma (PDAC), a form of locally advanced pancreatic cancer. This designation underscores its promise in addressing a crucial therapeutic void for this severe cancer, particularly following encouraging outcomes from Phase 2 clinical trials that demonstrated notable clinical benefits and anti-cancer activity in patients with metastatic PDAC.
Locally Advanced Pancreatic Cancer Market Leading Players Shaping Industry Direction
Major companies operating in the locally advanced pancreatic cancer market are Pfizer Inc, F Hoffmann La Roche Ltd, Merck and Co Inc, Bristol Myers Squibb Company, AstraZeneca plc, AbbVie Inc, Novartis AG, GSK plc, Bayer AG, Eli Lilly and Company, Ipsen, Takeda Pharmaceutical Company Limited, Amgen Inc, Sanofi, Servier, NovoCure Limited, Halozyme Therapeutics, Clovis Oncology, Astellas Pharma, BeiGene
Access The Complete Locally Advanced Pancreatic Cancer Market Report:
Locally Advanced Pancreatic Cancer Market Geographic Analysis: Where Is Demand Growing The Fastest?
North Americawas the largest region in the locally advanced pancreatic cancer market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the locally advanced pancreatic cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
